Sahlgrenska Science Park participated at BIO-Europe Spring in Stockholm and with us was Stayble Therapeutics and Emeriti Pharma. Both companies had intense days with many interesting one-to-one meetings. David Gustafsson also made a very good pitch for Emeriti Pharma during the Start-Up Slam.
Emeriti Pharma develops a new treatment for the skin disease rosacea. The company that is coached by Sahlgrenska Science Park is based at AstraZeneca Bioventure Hub. Already this autumn a clinical study (Phase 1) will start at Gothia Forum in Gothenburg.
“It was a good opportunity for us to take part of BIO-Europe Spring. We are now in a stage of development where we are looking for funding or pharmaceutical partners to continue after the Phase I study, “says David Gustafsson, CEO of Emeriti Pharma.
Rosacea is a chronic, inflammatory skin disease that attacks parts of the face with redness and sometimes acne-like lesions. There is a medical need for new drugs that work faster and have a better effect than current treatments, not least to reduce the redness and reduce the use of antibiotics. Emeriti Pharmas’ concept for a cream with the active substance EP0003 involves inhibiting a specific enzyme which is involved in the development of the disease.
For more information, please contact David v g Gustafsson, CEO of Emeriti Pharma, tel 070-695 15:34 or e-mail email@example.com